Korean biotech specializing in antibody-drug-conjugate (ADC) linker technology, licensed to global pharma partners for cancer drugs.
Korean biotech specializing in antibody-drug-conjugate (ADC) linker technology, licensed to global pharma partners for cancer drugs.
Earns upfront and milestone payments when pharma partners license its drug candidates or linker technology, rather than from product sales, so income arrives in lumps and depends on partners advancing programmes. A royalty stream would only follow approvals.
Moat: narrow (IP / patents). Patented, versatile ADC linker platform licensed to multiple global pharma companies.
Headquarters: Daejeon, South Korea · Founded: 2006 · Employees: 180
Size LigaChem Biosciences (141080.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.48B, the 176th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩53,900 on 18 Nov 2026.
Performance Over six months the shares fell 72.5%, against -8.4% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 54.9% over the last twelve months (peer median +4.1%); the operating margin is -324.4% (peer median 12.0%).
Valuation It trades at 17.0× enterprise value to sales against a peer median of 3.5× (4th most expensive of 20).
Capital Return on invested capital runs 136.7 points below its cost of capital (5.9% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩71.9B | ₩142B | ₩126B | ₩34.1B | ₩33.4B |
| Revenue growth | — | +12% | +269% | +2% | — |
| Gross profit | ₩56.2B | ₩122B | ₩107B | ₩15.6B | ₩15.8B |
| EBITDA | -₩226B | -₩100B | -₩16.0B | -₩76.9B | -₩50.9B |
| Net income | -₩219B | -₩74.3B | ₩7.80B | -₩73.7B | -₩45.1B |
| Free cash flow | -₩235B | -₩128B | ₩75.8B | -₩63.6B | -₩11.3B |
| Capital expenditure | ₩6.80B | ₩6.04B | ₩5.70B | ₩2.20B | ₩4.77B |
| Total debt | ₩32.4B | ₩2.75B | ₩820M | ₩12.6B | ₩12.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| LigaChem Biosciences 141080.KS | $1.48B | -72% | -55% | -324% | 17.0× | n/a |
| ABL Bio 298380.KS | $1.51B | -71% | -53% | -201% | 46.5× | n/a |
| Aimed Bio 0009K0.KS | $778M | -61% | +228% | 34% | 13.8× | 10.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 141080.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.9% | -3.8% | 2nd lowest of 21 |
| 6-month return | -72.5% | -8.4% | lowest of 21 |
| Distance from 52-week high | -76.0% | -40.1% | 2nd lowest of 21 |
| Revenue growth (TTM) | -54.9% | +4.1% | 2nd lowest of 20 |
| Operating margin | -324.4% | 12.0% | 2nd lowest of 20 |
| EV / Sales | 17.0× | 3.5× | 4th most expensive of 20 |
| ROIC minus cost of capital | -136.7 pp | -0.2 pp | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | 17.0× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 8.9× | 36.3% | +16.6% |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | 46.5× | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 3.1× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 1.4× | -6.4% | +12.7% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | 3.5× | -4.9% | +0.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 1.4× | -6.1% | +1.9% |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | 216.0× | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | 85,633.6× | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 3.8× | 31.0% | +16.6% |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 0.8× | -18.1% | +7.0% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | 0.9× | -6.8% | +32.4% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 2.5× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 2.1× | -9.6% | +4.6% |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 4.5× | 6.0% | -4.3% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 2.0× | n/a | n/a |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 1.2× | -6.6% | -5.6% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 5.2× | 12.8% | -14.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 9.8× | 31.1% | -15.1% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 7.2× | n/a | n/a |